DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 193.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,097 shares of the medical device company's stock after buying an additional 11,273 shares during the quarter. SG Americas Securities LLC's holdings in DexCom were worth $1,168,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of DXCM. Brighton Jones LLC grew its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Empowered Funds LLC grew its position in DexCom by 37.0% during the 4th quarter. Empowered Funds LLC now owns 8,010 shares of the medical device company's stock worth $623,000 after acquiring an additional 2,163 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in DexCom by 28.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company's stock worth $4,596,000 after purchasing an additional 13,111 shares in the last quarter. Van ECK Associates Corp boosted its stake in DexCom by 325.0% in the fourth quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock worth $6,674,000 after purchasing an additional 65,622 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG grew its holdings in shares of DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DXCM. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Finally, Barclays boosted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

Insider Activity

In other news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president now directly owns 95,602 shares of the company's stock, valued at $8,057,336.56. The trade was a 9.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,474 shares of company stock valued at $1,887,026 over the last 90 days. Insiders own 0.32% of the company's stock.

DexCom Stock Performance

DexCom stock traded down $0.45 during midday trading on Wednesday, hitting $81.38. 274,876 shares of the company's stock were exchanged, compared to its average volume of 4,328,596. The stock has a market cap of $31.91 billion, a price-to-earnings ratio of 60.62, a price-to-earnings-growth ratio of 1.77 and a beta of 1.46. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.49. The firm's 50 day simple moving average is $79.25 and its 200 day simple moving average is $79.38. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the firm posted $0.32 EPS. The company's revenue for the quarter was up 12.5% on a year-over-year basis. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.